Floatz logo

Ipilimumab

Advanced or Metastatic Solid Tumors

Bristol-Myers Squibbmonoclonal_antibodyPhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Advanced or Metastatic Solid Tumors cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Beijing Biotech
Phase 1/2B
Pembrolizumab
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Epirubicin
Hanmi Pharmaceutical Company Limited
Phase 1/2B
Eloxatin
ASLAN Pharmaceuticals
Phase 1/2CCC
Pemigatinib
Incyte Corporation
Phase 2CCC

View all 50 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →